Status:
UNKNOWN
Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
Lead Sponsor:
Xing Xie, MD
Conditions:
Human Papilloma Virus
Cervical Cancer
Eligibility:
FEMALE
18-65 years
Brief Summary
Human papilloma virus (HPV) infection contributes as a main causative factor to the development of invasive cervical cancer (ICC) and its precursors (cervical intraepithelial neoplasia, CIN). Currentl...
Detailed Description
The incidence of cervical cancer estimated to be 500,000 cases per year with a 50% case fatality rate. Human papilloma virus (HPV) infection, which is the most common sexually transmitted viral infect...
Eligibility Criteria
Inclusion
- Women with histologically confirmed CIN1, CIN2, CIN3 or invasive cervical cancer (ICC)
Exclusion
- Women with a history of immunodeficiency disorders, including HIV, and those who had undergone chemoradiotherapy for cervical cancer were excluded.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2013
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT01487681
Start Date
November 1 2011
End Date
October 1 2013
Last Update
December 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's hospital, School of medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310006